Study Assessing Use of Mood Stabilizers (Sodium Valproate and Oxcarbazepine) as an Augmentation Strategy in Patients of Treatment-resistant Depression
Annals of Indian Psychiatry · 2025
DOI: 10.4103/aip.aip_107_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Indian Psychiatry, 2025. Verfasst von Priya Chugh und 1 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Themen: Depression
Abstract (Originalsprache)
Background
Treatment-resistant depression (TRD) is a major challenge, with a significant proportion of patients failing to achieve remission with initial antidepressant treatment. As per literature, augmentation strategies using nonantidepressant agents have been explored to overcome partial or lack of response. This study aimed to determine the efficacy of adding mood stabilizers, sodium valproate, and oxcarbazepine as augmenting agents in patients with TRD. Methodology: This prospective and observational study recruited 106 patients with TRD from a tertiary care center in Navi Mumbai, India. Patients were augmented with either sodium valproate ( n = 53) or oxcarbazepine ( n = 53) in addition to their ongoing antidepressant and anti-anxiety medications. The Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A) were administered at baseline, at 2 weeks, and at 4 weeks after augmentation. Treatment response was documented, and results were statistically analyzed.
Results
Both augmentation groups showed significant improvements in HAM-D and HAM-A scores at 2 and 4 weeks compared to baseline ( P < 0.001). However, the sodium valproate group demonstrated superior efficacy, with a greater reduction in HAM-D scores as compared to the oxcarbazepine group at 2 weeks (25.60 vs. 21.98, P = 0.001) and 4 weeks (34.06 vs. 30.64, P = 0.001).
Conclusion
The addition of mood stabilizers, sodium valproate, and oxcarbazepine, as augmentation agents led to significant improvement in patients with TRD. Sodium valproate exhibited superior efficacy as compared to oxcarbazepine, suggesting its potential as a valuable augmentation strategy in the management of TRD.
Zitieren
APA
Chugh, P., & Mahapatro, F. (2025). Study Assessing Use of Mood Stabilizers (Sodium Valproate and Oxcarbazepine) as an Augmentation Strategy in Patients of Treatment-resistant Depression. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_107_24
Vancouver
Chugh P, Mahapatro F. Study Assessing Use of Mood Stabilizers (Sodium Valproate and Oxcarbazepine) as an Augmentation Strategy in Patients of Treatment-resistant Depression. Annals of Indian Psychiatry. 2025. doi:10.4103/aip.aip_107_24
BibTeX
@article{Chugh2025,
author = {Chugh, Priya and Mahapatro, Fiona},
title = {Study Assessing Use of Mood Stabilizers (Sodium Valproate and Oxcarbazepine) as an Augmentation Strategy in Patients of Treatment-resistant Depression},
journal = {Annals of Indian Psychiatry},
year = {2025},
doi = {10.4103/aip.aip_107_24}
}
EUVIMED